Application of biomarkers in cancer prevention;Biomarkerek alkalmazása a rákprevencióban

Orvosi Hetilap

Volumn 147, Issue 14, 2006, Pages 627-636

  Tompa, Anna ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NONE   (Hungary)

Author keywords

Biomarkers; Cancer prevention; Chromosomal aberration; DNA damage; Genotoxicology; Immuntoxicology

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; MINERAL; VITAMIN; TUMOR MARKER;

ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME STRUCTURE; CYTOGENETICS; DRINKING BEHAVIOR; DRUG EXPOSURE; DRUG MECHANISM; GENE MUTATION; GENETIC DAMAGE; GENOMICS; HAZARD; HIGH RISK POPULATION; HUMAN; HUNGARY; LIFESTYLE MODIFICATION; LYMPHOCYTE CULTURE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL PRACTICE; METHODOLOGY; MOLECULAR GENETICS; ONCOGENE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRESCRIPTION; PRIMARY PREVENTION; SMOKING; TUMOR SUPPRESSOR GENE; BLOOD; DNA DAMAGE; ETHICS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; NEOPLASM; REVIEW;

CHROMOSOME ABERRATIONS; DNA DAMAGE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745304462     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bonassi, S., Hagmar, L., Strömberg, U. és mtsai: Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res., 2000, 60, 1619-1625.
2. Biró, A., Pallinger, E., Major, J. és mtsai: Lymphocyte phenotype analysis and chromosome aberration frequency of workers occupationally exposed to styrene, benzene, polycyclic aromatic hydrocarbons or mixed solvents. Immunol Lett., 2002, 81, 133-40.
3. Carrano, A. V., Natarajan, A. T.: Consideration for population monitoring using cytogenetic techniques. Mutat. Res., 1988, 204, 379-406.
4. Damme, C. J.: Legal implication of monitoring workers for carcinogenic and mutagenic risk, Teratogen. Carcinogen. Mutagen., 1982, 2, 211-219.
5. Deutsch T., Gergely T.: A genomikus medicina informatikája, Magyar Tudomány, 2005, 1, 70-80.
6. Doll, R., Peto, R.: The causes of cancer: quantitative estimates of avoidable risk of cancer int the United States today. J. Natl. Cancer Inst., 1981, 66, 1191-1208.
7. Dunn, B. P., Stich, H. F.: 32P postlabeling analysis of aromatic DNA adducts in human oral mucosa cells. Carcinogenesis, 1986, 7, 1115-1120.
8. Evans, H. J., O'Riordan, M.: Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. Mutat. Res., 1975, 31, 135-148.
9. EEC (1990) Directive 90/394/EEC on the protection of workers from the risk related to exposure of carcinogens at work, PbEC 1990 L 196/ 1.
10. Ember I., Kiss I., Sándor J. és mtsai: A korai biomarkerek használata a prevencia-óban. LAM. 2003, 13, 547-554.
11. Evans, H. J.: Chromosomal mutations in human populations, Cytogenet. Cell Genet., 1982, 33, 48-56.
12. Falus A., Berke T., Ortutay Cs. P. és mtsa: Új tudományág az orvosi kutatás és klinikai gyakorlat középpontjában. LAM, 2004, 14, 33-39.
13. Gundy, S., Varga, P. L.: Chromosomal aberrations in healthy persons. Mutat. Res., 1983, 120, 187-191.
14. Gundy, S.: Cytogenetical studies on a large populations occupationally exposed to radiation and/ or to chemicals. Ann. Inst. Super. Sanita, 1989, 25, 549-556.
15. Hsu, T. C.: Genetic predisposition to cancer with special reference to mutagen sensitivity. In vitro Cell Dev. Biol., 1987, 23, 591-603.
16. Khoury, M. J., Burke, W., Thomson, E.: Genetics and Public Health: an overview In: Genetics and Public int he 21st Century http:// www.cdc.gov/genomics/info/books/21stcent1.htm. Oxford University Press, Oxford, 2000.
17. Lowe, S. W., Lin, A. W.: Apoptosis in cancer. Carcinogenesis, 2000, 21, 485-495.
18. Major, J., Jakab, M. G., Tompa, A.: Multiple end-point genotoxicology monitoring of Hungarian historical and industrial control subjects Centr. Eur. J. Occup. Environ. Med., 1997, 3, 87-101.
19. Major, J., Jakab, M. G., Tompa, A.: Genotoxicological monitoring of 175 subjects living in the greenbelts, inner town or near chemical industrial estates in greater Budapest agglomeration in Hungary. Mutat. Res., 1998, 412, 9-16.
20. Major J., Jakab M., Biró A. és mtsai: Chemoprevention by a chelating agent among galvanisers and goldsmiths occupationally exposed to non-ferrous, precious and heavy metals. In Metal Ions in Biology and Medicine (Szerk.: Cser, A A., Sziklai, L. I., Étienne, J.-C. és mtsai) John Libbey, Paris. 2004, 8, 548/551. old.
21. Medlin, J.F.: Timely toxicology. Environ. Health Perspect., 1999, 107, A256-258.
22. Nordic Study Group on the Risk of Chromosome Damage: A Nordic database on somatic chromosome damage in humans. Mutat. Res., 1990, 241, 325-337.
23. Oláh, E.: A DNS-molekulától a betegágyig: a molekuláris medicina hídja, Magyar Tudomány, 2003, 5, 582-592.
24. Oláh E.: Örökletes daganatos megbetegedések. (Öröklött rákhajlam és rákszindrómák). Orv. Hetil., 1999, 140, 451-466.
25. Oláh E.: Molekuláris onkológia a rákgenomika elso évtizedében. Magyar Tudomány (megjelenés alatt).
26. Oláh E.: A BRCAI ş BRCA2 gének. Magyar Tudomány, 2005, 8, 989-1000.
27. Olshan, A. F., Weissler, M. C., Watson, M. A. és mtsai: GSTM1,GSTT1,GSTP1,CYPA1 and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol. Biomark. Prev., 2000, 9, 185-191.
28. Paolini, M., Abdel-Rahman, S. Z., Sapone, A. és mtsai: Beta-carotene: a cancer chemopreventive agent or a co-carcinogen? Mutat. Res., 2003, 543, 195-200.
29. Sablina, A. A., Budanov, A. V. és mtsai: The antioxidant function of the p53 tumor suppressor. Nature Medicine, 2005, 11, 1306-1313.
30. Sehocket B.: A dohányzásból származó DNS-adduktok szerepe a karcinogenezisben. Magyar Onkológia, 2004, 48, 201-205.
31. Schwartz, J. L.: Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit. Rev. Oral. Biol. Med., 2000, 11, 92-122.
32. Székely G., Remenár É., Kásler M. és mtsai: A kromoszómaanalízis és bleomycin-teszt hazai alkalmazhatóságának vizsgálata a fej-nyaki laphámrák prevenciójában. Orv. Hetil., 2001, 142, 611-616.
33. Takahashi, Y. Mai, M, Nishioka, K.: Difluoromethylomithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model. Int. J. Cancer., 2000, 85, 243-248.
34. Tompa A., Major J.: Genotoxikológia. In Klinikai Genetika. Szerk.: Papp, Z. Golden Book, Budapest, 1995, 141-156. old.
35. Tompa A., Major J., Jakab M. G. és mtsa: Géntoxikológiai és immuntoxikológiai vizsgálatok az egézségkockázat meghatározásában. Egészségtudomány, 2001, 45, 213-227.
36. Tompa, A., Sápi, É.: Detection of 6-thioguanine resistance in human peripherial blood lymphocytes (PBL) of industrial workers and lung cancer patients. Mutat. Res., 1989, 210, 345-351.
37. Tompa, A., Major, J., Jakab, M. G.: Monitoring of benzene-exposed workers for genotoxic effects of benzene: Improved-working condition related decrease in the frequencies of chromosomal aberrations in peripheral blood lymphocytes. Mutat. Res., 1994, 304, 159-165.
38. Tompa, A., Major, J., Jakab, M. G.: Is breast cancer duster influenced by environmental and occupational factors among hospital nurses in Hungary. Pathol. Oncol. Res., 1999, 5, 117-121.
39. Tompa A.: A humán géntoxikológiai biomarkerek prediktivitása a betegségek megelozésében. 2004, 48, 117-120.
40. Tompa A., Szende B.: Megelozo Orvostudomány: biomonitorozás és kemoprevenció. 2002, 46, 147-153.